These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23285253)

  • 1. HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
    Perrin S; Cremer J; Faucher O; Reynes J; Dellamonica P; Micallef J; Solas C; Lacarelle B; Stretti C; Kaspi E; Robaglia-Schlupp A; Nicolino-Brunet C; Tamalet C; Lévy N; Poizot-Martin I; Cau P; Roll P
    PLoS One; 2012; 7(12):e53035. PubMed ID: 23285253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
    Coffinier C; Hudon SE; Lee R; Farber EA; Nobumori C; Miner JH; Andres DA; Spielmann HP; Hrycyna CA; Fong LG; Young SG
    J Biol Chem; 2008 Apr; 283(15):9797-804. PubMed ID: 18230615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
    Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
    HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
    Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
    Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of selective ritonavir nonadherence and dose-staggering in recipients of boosted HIV-1 protease inhibitor therapy.
    Shuter J; Sarlo JA; Rode RA; Zingman BS
    HIV Clin Trials; 2009; 10(3):135-42. PubMed ID: 19632952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
    Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
    Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 "Aging" study.
    Perrin S; Cremer J; Roll P; Faucher O; Ménard A; Reynes J; Dellamonica P; Naqvi A; Micallef J; Jouve E; Tamalet C; Solas C; Pissier C; Arnoux I; Nicolino-Brunet C; Espinosa L; Lévy N; Kaspi E; Robaglia-Schlupp A; Poizot-Martin I; Cau P
    PLoS One; 2012; 7(7):e41129. PubMed ID: 22829920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen.
    Barrail-Tran A; Morand-Joubert L; Poizat G; Raguin G; Le Tiec C; Clavel F; Dam E; Chêne G; Girard PM; Taburet AM;
    Antimicrob Agents Chemother; 2008 May; 52(5):1642-6. PubMed ID: 18285478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
    d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
    Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir.
    Chaillou S; Durant J; Garraffo R; Georgenthum E; Roptin C; Clevenbergh P; Dunais B; Mondain V; Roger PM; Dellamonica P
    HIV Clin Trials; 2002; 3(6):493-501. PubMed ID: 12501133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
    Molina JM; Lamarca A; Andrade-Villanueva J; Clotet B; Clumeck N; Liu YP; Zhong L; Margot N; Cheng AK; Chuck SL;
    Lancet Infect Dis; 2012 Jan; 12(1):27-35. PubMed ID: 22015077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
    Karlström O; Josephson F; Sönnerborg A
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
    Bernal E; Masiá M; Padilla S; Ramos JM; Martín-Hidalgo A; Gutiérrez F
    Med Clin (Barc); 2007 Jul; 129(7):252-4. PubMed ID: 17683706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.
    Rusconi S; Giacomet V; Mameli C; Viganò A; Viganò O; Adorni F; Galli M; Zuccotti GV
    BMC Infect Dis; 2012 Aug; 12():179. PubMed ID: 22866946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
    Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
    Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.